Provided by Tiger Fintech (Singapore) Pte. Ltd.

Kalvista Pharmaceuticals Inc

15.56
+0.17001.10%
Post-market: 15.26-0.3000-1.93%19:39 EDT
Volume:710.64K
Turnover:11.05M
Market Cap:774.30M
PE:-4.21
High:15.74
Open:15.42
Low:15.20
Close:15.39
Loading ...

US FDA approves KalVista Pharma's swelling disorder drug

Reuters
·
07 Jul

Kalvista Pharmaceuticals Announces FDA Approval of Ekterly® (Sebetralstat), First and Only Oral on-Demand Treatment for Hereditary Angioedema

THOMSON REUTERS
·
07 Jul

Kalvista Pharmaceuticals Inc - Launches Ekterly in U.S., Prescriptions Available

THOMSON REUTERS
·
07 Jul

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
03 Jul

BRIEF-Kalvista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
03 Jul

KalVista Pharmaceuticals Announces Inducement Stock Option Grants for New Employees Under Nasdaq Rule 5635(c)(4)

Reuters
·
03 Jul

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
30 Jun

BRIEF-Kalvista Pharmaceuticals Enters Into Licensing Agreement With Pendopharm To Commercialize Sebetralstat For Hae In Canada

Reuters
·
26 Jun

Kalvista Pharmaceuticals Inc: Financial Terms of Agreement Are Not Being Disclosed

THOMSON REUTERS
·
26 Jun

Kalvista Pharmaceuticals Enters Into Licensing Agreement With Pendopharm to Commercialize Sebetralstat for Hae in Canada

THOMSON REUTERS
·
26 Jun

FDA Commissioner pushed to reject KalVista drug, Endpoints News says

TIPRANKS
·
25 Jun

KalVista volatile after Endpoints report on FDA Commissioner objection

TIPRANKS
·
25 Jun

KalVista trading resumes

TIPRANKS
·
25 Jun

Analysts Offer Insights on Healthcare Companies: Immuneering (IMRX) and KalVista Pharmaceuticals (KALV)

TIPRANKS
·
17 Jun

BUZZ-U.S. STOCKS ON THE MOVE-Eaton, Roku, PayPal

Reuters
·
16 Jun

Kalvista Pharmaceuticals Shares Down 4.8% After US FDA Extends Review of Co's Swelling Disorder Drug

THOMSON REUTERS
·
16 Jun

BUZZ-U.S. STOCKS ON THE MOVE-EchoStar, T1 Energy, Smurfit Westrock

Reuters
·
16 Jun

Citizens JMP Keeps Their Buy Rating on KalVista Pharmaceuticals (KALV)

TIPRANKS
·
16 Jun

KalVista Pharmaceuticals Unveils Promising Data on Sebetralstat for On-Demand HAE Attack Treatment at EAACI Congress 2025

Reuters
·
16 Jun

BUZZ-KalVista falls as FDA extends swelling disorder drug review

Reuters
·
16 Jun